Preventing Lung Cancer by Treating Tobacco Dependence

Clinics in Chest Medicine

Volumn 32, Issue 4, 2011, Pages 645-657

  Hurt, Richard D ^a   Ebbert, Jon O ^a   Hays, J Taylor ^a   McFadden, David D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Preventing lung cancer; Smoking; Tobacco treatment specialists

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NOSE SPRAY; PLACEBO; VARENICLINE;

BEHAVIOR THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CIGARETTE SMOKING; CLINICAL DECISION MAKING; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DOSE RESPONSE; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPIDEMIC; HUMAN; INHALER; LOZENGE; LUNG CANCER; MONOTHERAPY; NAUSEA; NEUROBIOLOGY; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SMOKING CESSATION; THORAX RADIOGRAPHY; TOBACCO DEPENDENCE; UNITED STATES; VIVID DREAM;

DECISION SUPPORT TECHNIQUES; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SMOKING; TOBACCO USE CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 80455167884     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.08.004     Document Type: Review

References (70)

1. Aldler I. Primary malignant growths of the lung. Primary malignant growths of the lungs and bronchi 1912, Longmans, Green and Co, London, Bombay (India), Calcutta (India), p. 1-12.
2. Ochsner A., DeBakey M. Carcinoma of the lung. Arch Surg 1941, 42:209-258.
3. Wynder E.L., Graham E.A. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma; a study of 684 proved cases. J Am Med Assoc 1950, 143(4):329-336.
4. Jemal A., Siegel R., Xu J., et al. Cancer statistics, 2010. CA Cancer J Clin 2010, 60(5):277-300.
5. Centers for Disease Control and Prevention. Tobacco use, targeting the nation's leading killer at a glance 2011. Chronic disease prevention and health promotion 2011. Available at: Accessed April 20, 2011. http://www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2011/Tobacco_AAG_2011_508.pdf.
6. McNally W. The tar in cigarette smoke and its possible effects. Am J Cancer 1932, 162:1502-1514.
7. Hurt R.D., Robertson C.R. Prying open the door to the tobacco industry's secrets about nicotine: the Minnesota Tobacco Trial. JAMA 1998, 280(13):1173-1181.
8. Smoking and health proposal. UCSF Legacy Tobacco Documents Library, Brown & Williamson Collection; 1969. Available at: Accessed April 20, 2011. http://legacy.library.ucsf.edu/tid/ypb72d00.
9. Janssen-Heijnen M.L., Coebergh J.W., Klinkhamer P.J., et al. Is there a common etiology for the rising incidence of and decreasing survival with adenocarcinoma of the lung?. Epidemiology 2001, 12(2):256-258.
10. Kozlowski L.T., Goldberg M.E., Yost B.A., et al. Smokers' misperceptions of light and ultra-light cigarettes may keep them smoking. Am J Prev Med 1998, 15(1):9-16.
11. US Department of Health and Human Services A report of the surgeon general 1990, Public Health Service, Centers for Disease Control, Office on Smoking and Health, Washington, DC.
12. Peto R., Lopez A.D. The future worldwide health effects of current smoking patterns. Critical issues in global health 2000, Jossey-Bass, New York, Available at: http://www.cdc.gov/chronicdisease/resources/publications/aag/pdf/2011/Tobacco_AAG_2011_508.pdf. Accessed August 8, 2011. C.E. Koop, C.E. Pearson, M.R. Schwarz (Eds.).
13. Fiore MC, Jaen C, Baker TB, et al. Treating tobacco use and dependence: 2008 update U.S. Surgeon General, Clinical Practice Guideline. Availabe at: http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf.
14. Swartz S.H., Cowan T.M., Klayman J.E., et al. Use and effectiveness of tobacco telephone counseling and nicotine therapy in Maine. Am J Prev Med 2005, 29(4):288-294.
15. Fiore M., Jaen C., Baker T., et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008, 35(2):158-176.
16. Brody A.L., Mandelkern M.A., London E.D., et al. Effect of secondhand smoke on occupancy of nicotinic acetylcholine receptors in brain. Arch Gen Psychiatry 2011, 68:953-960.
17. Watkins S.S., Koob G.F., Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000, 2(1):19-37.
18. Balfour D. The neurochemical mechanisms underlying nicotine tolerance and dependence. The biological basis of drug tolerance and dependence 1991, 121-151. Academic Press, London. J.A. Pratt (Ed.).
19. Perry D., Davila-Garcia M., Stockmeier C. Increased nicotine receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999, 289(3):1545-1552.
20. Hope B.T., Nagarkar D., Leonard S., et al. Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. J Neurosci 2007, 27(8):1964-1972.
21. Kenny P.J., Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci 2005, 25(26):6208-6212.
22. Dale L.C., Hurt R.D., Offord K.P., et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA 1995, 274(17):1353-1358.
23. Gourlay S.G., Benowitz N.L. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther 1997, 62(4):453-463.
24. Ho M.K., Mwenifumbo J.C., Al Koudsi N., et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 2009, 85(6):635-643.
25. Henningfield J.E., Stapleton J.M., Benowitz N.L., et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend 1993, 33(1):23-29.
26. Jacob P., Yu L., Shulgin A.T., et al. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 1999, 89(5):731-736.
27. Moyer T.P., Charlson J.R., Enger R.J., et al. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem 2002, 48(9):1460-1471.
28. Jacob P., Hatsukami D., Severson H., et al. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 2002, 11(12):1668-1673.
29. Piper M.E., Smith S.S., Schlam T.R., et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry 2009, 66(11):1253-1262.
30. Ebbert J.O., Severson H.H., Croghan I.T., et al. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. Nicotine Tob Res 2009, 11(12):1415-1423.
31. Shiffman S., Dresler C.M., Hajek P., et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med 2002, 162(11):1267-1276.
32. Schneider N.G., Olmstead R., Mody F.V., et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction 1995, 90(12):1671-1682.
33. Hurt R.D., Offord K.P., Croghan I.T., et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl) 1998, 140(1):98-104.
34. Leischow S., Nilsson F., Franzon M., et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav 1996, 20(5):364-371.
35. Bergstrom M., Nordberg A., Lunell E., et al. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharmacol Ther 1995, 57(3):309-317.
36. Hurt R.D., Dale L.C., Offord K.P., et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther 1993, 54(1):98-106.
37. Hurt R.D., Dale L.C., Fredrickson P.A., et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA 1994, 271(8):595-600.
38. Hughes J.R., Lesmes G.R., Hatsukami D.K., et al. Are higher doses of nicotine replacement more effective for smoking cessation?. Nicotine Tob Res 1999, 1(2):169-174.
39. Stead L.F., Perera R., Bullen C., et al. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systemic Reviews 2008, 1:CD000146.
40. Jorenby D.E., Smith S.S., Fiore M.C., et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA 1995, 274(17):1347-1352.
41. Kenford S.L., Fiore M.C., Jorenby D.E., et al. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA 1994, 271(8):589-594.
42. Schnoll R.A., Patterson F., Wileyto E.P., et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010, 152(3):144-151.
43. Steinberg M.B., Greenhaus S., Schmelzer A.C., et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009, 150(7):447-454.
44. Clarke P.B. Nicotine dependence-mechanisms and therapeutic strategies. Biochem Soc Symp 1993, 59:83-95.
45. Pontieri F.E., Tanda G., Orzi F., et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 1996, 382(6588):255-257.
46. Fryer J.D., Lukas R.J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999, 288(1):88-92.
47. Hurt R.D., Sachs D.P., Glover E.D., et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997, 337(17):1195-1202.
48. Hays J.T., Hurt R.D., Rigotti N.A., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 2001, 135(6):423-433.
49. Gonzales D.H., Nides M.A., Ferry L.H., et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther 2001, 69(6):438-444.
50. Tashkin D., Kanner R., Bailey W., et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001, 357(9268):1571-1575.
51. Tonstad S., Farsang C., Klaene G., et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003, 24(10):946-955.
52. Jorenby D.E., Leischow S.J., Nides M.A., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999, 340(9):685-691.
53. Rollema H., Chambers L.K., Coe J.W., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52(3):985-994.
54. Jorenby D.E., Hays J.T., Rigotti N.A., et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):56-63.
55. Gonzales D., Rennard S.I., Nides M., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):47-55.
56. Tonstad S., Tonnesen P., Hajek P., et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006, 296(1):64-71.
57. Rigotti N.A., Pipe A.L., Benowitz N.L., et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010, 121(2):221-229.
58. Tashkin D.P., Rennard S., Hays J.T., et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011, 139(3):591-599.
59. Williams C.R., Fiore M.C., Jaen C., et al. A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008, 35(2):158-176.
60. McClure J.B., Swan G.E., Jack L., et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 2009, 24(5):563-569.
61. Croghan I.T., Hurt R.D., Dakhil S.R., et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007, 82(2):186-195.
62. Ebbert J.O., Burke M.V., Hays J.T., et al. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009, 11(5):572-576.
63. Quinn V.P., Hollis J.F., Smith K.S., et al. Effectiveness of the 5-As tobacco cessation treatments in nine HMOs. J Gen Intern Med 2009, 24(2):149-154.
64. Hughes J. Tobacco treatments specialists: a new profession. J Smoking Cessation 2007, 2(Suppl):2-7.
65. Aberle D.R., Berg C.D., Black W.C., et al. The National Lung Screening Trial: overview and study design. Radiology 2011, 258(1):243-253.
66. National Lung Screening Trial Research Team Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
67. Gohagan J., Marcus P., Fagerstrom R., et al. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004, 126(1):114-121.
68. Gohagan J.K., Marcus P.M., Fagerstrom R.M., et al. Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer 2005, 47(1):9-15.
69. Taylor K.L., Cox L.S., Zincke N., et al. Lung cancer screening as a teachable moment for smoking cessation. Lung Cancer 2007, 56(1):125-134.
70. Croghan I.T., Offord K.P., Evans R.W., et al. Cost-effectiveness of treating nicotine dependence: the Mayo Clinic experience. Mayo Clin Proc 1997, 72(10):917-924.